{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-178937","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2024-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.392481+00:00","generated_at":"2026-05-31T20:43:26.729204+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pliant reports positive Phase 2a data for bexotegrast in PSC; 320 mg well tolerated up to 40 weeks","bullets":["320 mg cohort met primary safety endpoint; no treatment-related severe or serious adverse events.","Improvement in liver stiffness by transient elastography at Week 24 vs placebo.","Statistically significant reduction in alkaline phosphatase (ALP) over 24 weeks vs placebo.","MRI showed continued improvement in hepatocyte function and bile flow from Week 12 to 24.","FDA supportive of 52-week Phase 2b trial with non-invasive endpoints; program path being evaluated."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-178937","json":"https://secwatch.observer/filing/0001193125-24-178937.json","markdown":"https://secwatch.observer/filing/0001193125-24-178937.md","text":"https://secwatch.observer/filing/0001193125-24-178937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312524178937/0001193125-24-178937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312524178937/d829862d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:43:26.729204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}